Monoclonal antibodies specific to the plexin-semaphorin-integrin (PSI) domain of RON for drug delivery and its application in cancer therapy
US11208494B2 · kind B2 · utility
1Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 1, 2019 |
| Grant date | Dec 28, 2021 |
| Priority date | — |
| Expiry date | Aug 1, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention includes unique, isolated monoclonal antibodies that bind the PSI domain of human RON (RONPSI), and methods for making and using the same and novel combination therapies of anti-RONPSI antibodies, including humanized anti-RONPSI antibodies, nucleic acids that encode the heavy chain, the light chain, or both the light and heave chains of the antibody, host cells, expression vectors, and wherein the antibody or binding fragments thereof can be further conjugated with one or more cytotoxic or chemotherapeutic agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.